Modulation of interferon expression by hepatitis C virus NS5A protein and human homeodomain protein PTX1

Virology

Volumn 306, Issue 1, 2003, Pages 51-59

  Ghosh, Asish K ^a   Majumder, Mainak ^a   Steele, Robert ^a   Ray, Ranjit ^a,b   Ray, Ratna B ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HOMEODOMAIN PROTEIN; HYBRID PROTEIN; INTERFERON REGULATORY FACTOR 3; PROTEIN PTX1; UNCLASSIFIED DRUG;

ARTICLE; BIRD DISEASE; CELL STRAIN HEPG2; GENE ACTIVATION; GENETIC TRANSFECTION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MAMMAL; NEWCASTLE DISEASE PARAMYXOVIRUS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; TWO HYBRID SYSTEM;

CELL LINE; DNA-BINDING PROTEINS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; HUMANS; INTERFERON REGULATORY FACTOR-3; INTERFERON-ALPHA; NEWCASTLE DISEASE VIRUS; PAIRED BOX TRANSCRIPTION FACTORS; PRECIPITIN TESTS; PROMOTER REGIONS (GENETICS); TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TWO-HYBRID SYSTEM TECHNIQUES; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS; MAMMALIA; MURINAE; NEWCASTLE DISEASE VIRUS;

EID: 0037293053     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(02)00029-6     Document Type: Article

References (61)

1. Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection a perspective on long-term outcome. Semin. Liver Dis. 20:2000;17-35.
2. Au W.C., Moore P.A., LaFleur D.W., Tombal B., Pitha P.M. Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes. J. Biol. Chem. 273:1998;29210-29217.
3. Bartenschlager R. In vitro models for hepatitis C. Virus Res. 82:2002;25-32.
4. Bazzigher L., Pavlovic J., Haller O., Staeheli P. Mx genes show weaker primary response to virus than other interferon-regulated genes. Virology. 186:1992;154-160.
5. Bigger C.B., Brasky K.M., Lanford R.E. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J. Virol. 75:2001;7059-7066.
6. Blight K.J., Kolykhalov A.A., Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science. 290:2000;1972-1974.
7. Castelruiz Y., Larrea E., Boya P., Civeira M.P., Prieto J. Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls. Hepatology. 29:1999;1900-1904.
8. Castet V., Fournier C., Soulier A., Brillet R., Coste J., Larrey D., Dhumeaux D., Maurel P., Pawlotsky J.M. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol. 76:2002;8189-8199.
9. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 244:1989;359-362.
10. Chung R.T., He W., Saquib A., Contreras A.M., Xavier R.J., Chawla A., Wang T.C., Schmidt E.V. Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. Proc. Natl. Acad. Sci. USA. 98:2001;9847-9852.
11. Delhase M.© 2001 Elsevier Science Ltd., Castrillo J.L., de la Hoya M., Rajas F., Hooghe-Peters E.L. AP-1 and Oct-1 transcription factors down-regulate the expression of the human PIT1/GHF1 gene. J. Biol. Chem. 271:1996;32349-32358.
12. DiBisceglie A.M. Hepatitis C and hepatocellular carcinoma. Hepatology. 26:1997;S34-S38.
13. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Izumi N., Marumo F., Sato C. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J. Clin. Invest. 96:1995;224-230.
14. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Ogura Y., Izumi N., Marumo F., Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 334:1996;77-81.
15. Fredericksen B., Akkaraju G.R., Foy E., Wang C., Pflugheber J., Chen Z.J., Gale M. Jr. Activation of the interferon-beta promoter during hepatitis C virus RNA replication. Viral Immunol. 15:2002;29-40.
16. Gale M. Jr., Kwieciszewski B., Dossett M., Nakao H., Katze M.G. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J. Virol. 73:1999;6506-6516.
17. Ghosh A.K., Majumder M., Steele R., Yaciuk P., Chrivia J., Ray R., Ray R.B. Hepatitis C virus NS5A protein modulates transcription through a novel cellular transcription factor SRCAP. J. Biol. Chem. 275:2000;7184-7188.
18. Ghosh A.K., Majumder M., Steele R., Meyer K., Ray R., Ray R.B. Hepatitis C virus NS5A protein protects against TNF-alpha mediated apoptotic cell death. Virus Res. 67:2000;173-178.
19. Ghosh A.K., Steele R., Meyer K., Ray R., Ray R.B. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J. Gen. Virol. 80:1999;1179-1183.
20. Grakoui A., Wychowski C., Lin C., Feinstone S.M., Rice C.M. Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol. 67:1993;1385-1395.
21. Guo J.T., Bichko V.V., Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J. Virol. 75:2001;8516-8523.
22. Hayashi J., Aoki H., Arakawa Y., Hino O. Hepatitis C virus and hepatocarcinogenesis. Intervirology. 42:1999;205-210.
23. Hijikata M., Kato N., Ootsuyama Y., Nakagawa M., Shimotohno K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc. Natl. Acad. Sci. USA. 88:1991;5547-5551.
24. Hoofnagle J.H., Di Bisceglie A.M. The treatment of chronic viral hepatitis. N. Engl. J. Med. 336:1997;347-356.
25. Jaeckel E., Cornberg M., Wedemeyer H., Santantonio T., Mayer J., Zankel M., Pastore G., Dietrich M., Trautwein C., Manns M.P. Treatment of acute hepatitis C with interferon alfa-2b. N. Engl. J. Med. 345:2001;1452-1457.
26. Jakschies D., Zachoval R., Muller R., Manns M., Nolte K.U., Hochkeppel H.K., Horisberger M.A., Deicher H., Von Wussow P. Strong transient expression of the type I interferon-induced MxA protein in hepatitis A but not in acute hepatitis B and C. Hepatology. 19:1994;857-865.
27. Jeffers L. Hepatocellular carcinoma an emerging problem with hepatitis C. J. Natl. Med. Assoc. 92:2000;369-371.
28. Kaito M., Watanabe S., Tsukiyama-Kohara K., Yamaguchi K., Kobayashi Y., Konishi M., Yokoi M., Ishida S., Suzuki S., Kohara M. Hepatitis C virus particle detected by immunoelectron microscopic study. J. Gen. Virol. 75:1994;1755-1760.
29. Kaneko T., Tanji Y., Satoh S., Hijikata M., Asabe S., Kimura K., Shimotohno K. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem. Biophys. Res. Commun. 205:1994;320-326.
30. Kato N., Yokosuka O., Hosoda K., Ito Y., Ohto M., Omata M. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction increase of the virus in advanced liver disease. Hepatology. 18:1993;16-20.
31. Keskinen P., Nyqvist M., Sareneva T., Pirhonen J., Melen K., Julkunen I. Impaired antiviral response in human hepatoma cells. Virology. 263:1999;364-375.
32. Koev G., Duncan R.F., Lai M.M. Hepatitis C virus IRES-dependent translation is insensitive to an eIF2alpha-independent mechanism of inhibition by interferon in hepatocyte cell lines. Virology. 297:2002;195-202.
33. Kolykhalov A.A., Agapov E.V., Blight K.J., Mihalik K., Feinstone S.M., Rice C.M. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science. 277:1997;570-574.
34. Lin R., Mamane Y., Hiscott J. Multiple regulatory domains control IRF-7 activity in response to virus infection. J. Biol. Chem. 275:2000;34320-34327.
35. Lin R., Genin P., Mamane Y., Hiscott J. Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7. Mol. Cell. Biol. 20:2000;6342-6353.
36. Lopez S., Island M.L., Drouin J., Bandu M.T., Christeff N., Darracq N., Barbey R., Doly J., Thomas D., Navarro S. Repression of virus-induced interferon A promoters by homeodomain transcription factor Ptx1. Mol. Cell. Biol. 20:2000;7527-7540.
37. Majumder M., Ghosh A.K., Steele R., Ray R., Ray R.B. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J. Virol. 75:2001;1401-1407.
38. Majumder M., Ghosh A.K., Steele R., Zhou X.Y., Phillips N.J., Ray R., Ray R.B. Hepatitis C virus NS5A protein impairs TNF-mediated hepatic apoptosis, but not by an anti-FAS antibody, in transgenic mice. Virology. 294:2002;94-105.
39. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomised trial. Lancet. 358:2001;958-965.
40. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., Albrecht J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339:1998;1485-1492.
41. Moradpour D., Blum H.E. Current and evolving therapies for hepatitis C. Eur. J. Gastroenterol. Hepatol. 11:1999;1199-1202.
42. Nousbaum J.B., Pol S., Nalpas B., Landais P., Berthelot P., Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann. Intern. Med. 122:1995;161-168.
43. Patzwahl R., Meier V., Ramadori G., Mihm S. Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection detection by suppression-subtractive hybridization. J. Virol. 75:2001;1332-1338.
44. Polyak S.J., McArdle S., Liu S.L., Sullivan D.G., Chung M., Hofgartner W.T., Carithers R.L. Jr., McMahon B.J., Mullins J.I., Corey L., Gretch D.R. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J. Virol. 72:1998;4288-4296.
45. Poulin G., Turgeon B., Drouin J. NeuroD1/beta2 contributes to cell-specific transcription of the proopiomelanocortin gene. Mol. Cell. Biol. 17:1997;6673-6682.
46. Poynard T., Leroy V., Cohard M., Thevenot T., Mathurin P., Opolon P., Zarski J.P. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C effects of dose and duration. Hepatology. 24:1996;778-789.
47. Reed K.E., Rice C.M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Top. Microbiol. Immunol. 242:2000;55-84.
48. Reed K.E., Xu J., Rice C.M. Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo properties of the NS5A-associated kinase. J. Virol. 71:1997;7187-7197.
49. Rosen H.R., Ribeiro R.R., Weinberger L., Wolf S., Chung M., Gretch D.R., Perelson A.S. Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. J. Hepatol. 37:2002;124-130.
50. Saito I., Miyamura T., Ohbayashi A., Harada H., Katayama T., Kikuchi S., Watanabe Y., Koi S., Onji M., Ohta Y., Choo Q., Houghton M., Kuo G. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA. 87:1990;6547-6549.
51. Schiappa D.A., Mittal C., Brown J.A., Mika B.P. Relationship of hepatitis C genotype 1 NS5A sequence mutations to early phase viral kinetics and interferon effectiveness. J. Infect. Dis. 185:2002;868-877.
52. Schuster A., Johnston I.C., Das T., Banerjeem A.K., Pavlovic J., ter Meulen V., Schneider-Schaulies S. Expression of the human MxA protein is associated with hyperphosphorylation of VSV P protein in human neural cells. Virology. 220:1996;241-245.
53. Sen G.C. Viruses and interferons. Annu. Rev. Microbiol. 55:2001;255-281.
54. Servant M.J., ten Oever B., LePage C., Conti L., Gessani S., Julkunen I., Lin R., Hiscott J. Identification of distinct signaling pathways leading to the phosphorylation of interferon regulatory factor 3. J. Biol. Chem. 27:2001;355-363.
55. Szeto D.P., Ryan A.K., O'Connell S.M., Rosenfeld M.G. P-OTX a PIT-1-interacting homeodomain factor expressed during anterior pituitary gland development. Proc. Natl. Acad. Sci. USA. 93:1996;7706-7710.
56. Tan S.L., Katze M.G. How hepatitis C virus counteracts the interferon response the jury is still out on NS5A. Virology. 284:2001;1-12.
57. Tanji Y., Kaneko T., Satoh S., Shimotohno K. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J. Virol. 69:1995;3980-3986.
58. Tremblay J.J., Drouin J. Egr-1 is a downstream effector of GnRH and synergizes by direct interaction with Ptx1 and SF-1 to enhance luteinizing hormone beta gene transcription. Mol. Cell. Biol. 19:1999;2567-2576.
59. Tremblay J.J., Marcil A., Gauthier Y., Drouin J. Ptx1 regulates SF-1 activity by an interaction that mimics the role of the ligand-binding domain. EMBO J. 18:1999;3431-3441.
60. Tremblay J.J., Goodyer C.G., Drouin J. Transcriptional properties of Ptx1 and Ptx2 isoforms. Neuroendocrinology. 71:2000;277-286.
61. Yanagi M., Purcell R.H., Emerson S.U., Bukh J. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc. Natl. Acad. Sci. USA. 94:1997;8738-8743.